hairy cell leukemia (Cancer)
Information
- Disease name
- hairy cell leukemia
- Disease ID
- DOID:285
- Description
- "A chronic lymphocytic leukemia that is characterized by over production of B cells (lymphocytes) by the bone marrow where the B cells appear hairy under a microscope." [url:https\://en.wikipedia.org/wiki/Hairy_cell_leukemia, url:https\://www.mayoclinic.org/diseases-conditions/hairy-cell-leukemia/symptoms-causes/syc-20372956, url:https\://www.ncbi.nlm.nih.gov/pubmed/30723113]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02362035 | Active, not recruiting | Phase 1/Phase 2 | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | February 20, 2015 | April 1, 2026 |
| NCT01059786 | Active, not recruiting | Phase 2 | Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia | July 1, 2010 | December 31, 2025 |
| NCT01711632 | Active, not recruiting | Phase 2 | BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia | October 2012 | October 2025 |
| NCT03805932 | Active, not recruiting | Phase 1 | Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia | October 3, 2019 | June 30, 2025 |
| NCT01841723 | Active, not recruiting | Phase 2 | Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | April 30, 2013 | December 31, 2024 |
| NCT03410875 | Active, not recruiting | Phase 2 | A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | February 9, 2018 | January 2025 |
| NCT00923013 | Active, not recruiting | Phase 2 | Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia | October 20, 2008 | December 31, 2025 |
| NCT00001567 | Completed | Phase 2 | A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia | January 1997 | April 2002 |
| NCT00321555 | Completed | Phase 2 | LMB-2 to Treat Hairy Cell Leukemia | May 2, 2006 | December 31, 2022 |
| NCT00586924 | Completed | Phase 1 | A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia | May 10, 2007 | May 6, 2015 |
| NCT00898079 | Completed | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | October 13, 2003 | June 30, 2018 | |
| NCT01720758 | Completed | Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease | November 2012 | April 2013 | |
| NCT03010358 | Completed | Phase 1/Phase 2 | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | July 17, 2017 | April 29, 2021 |
| NCT05645744 | Enrolling by invitation | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. | September 29, 2021 | July 2041 | |
| NCT05859932 | Not yet recruiting | Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients | June 2024 | June 2026 | |
| NCT02131753 | Recruiting | Phase 2/Phase 3 | Therapy Optimisation for the Treatment of Hairy Cell Leukemia | May 2004 | December 2027 |
| NCT06340737 | Recruiting | Phase 1 | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | March 29, 2024 | April 2031 |
| NCT00412594 | Recruiting | Phase 2 | Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia | June 10, 2004 | June 30, 2025 |
| NCT04322383 | Recruiting | Phase 2 | Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant | January 7, 2021 | July 31, 2028 |
| NCT04324112 | Recruiting | Phase 2 | Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | October 28, 2020 | July 31, 2028 |
| NCT04775745 | Recruiting | Phase 1 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | July 19, 2021 | December 31, 2025 |
| NCT04815356 | Recruiting | Phase 1 | Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant | May 23, 2022 | December 1, 2036 |
| NCT05388123 | Recruiting | Phase 2 | Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia | March 2, 2022 | January 1, 2025 |
| NCT00924040 | Terminated | Phase 2 | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | February 2009 | August 2010 |
| NCT04125290 | Terminated | US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) | December 9, 2019 | June 21, 2021 | |
| NCT02012231 | Terminated | Phase 1 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | February 2014 | June 2015 |
| NCT04952974 | Unknown status | B-cell Chronic Lymphoid Malignancies Markers | June 14, 2021 | March 30, 2023 | |
| NCT00462189 | Unknown status | Phase 1 | Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease | April 2007 | |
| NCT03739606 | Withdrawn | Phase 2 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | October 20, 2020 | October 20, 2020 |
- Disase is a (Disease Ontology)
- DOID:1040
- Cross Reference ID (Disease Ontology)
- GARD:6560
- Cross Reference ID (Disease Ontology)
- ICD10CM:C91.4
- Cross Reference ID (Disease Ontology)
- ICD9CM:202.4
- Cross Reference ID (Disease Ontology)
- ICDO:9940/3
- Cross Reference ID (Disease Ontology)
- MESH:D007943
- Cross Reference ID (Disease Ontology)
- NCI:C7402
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:118613001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023443